Yong Chen: Clinical Trials

4 unknown. 4 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	4	Unknown 4

Follow Yong Chen: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma Toripalimab combined with Temozolomide - Melanoma Stage III	Phase 2	Unknown	Yong Chen	20	2023-05-01	2023-04-25
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma SHR-1701, Temozolomide - Melanoma	Phase 2	Unknown	Yong Chen	31	2022-01-21	2023-06-07
Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment Endostar (recombinant human endostatin injection), Chemotherapy AI - Other Disorders of Soft Tissues	Phase 2	Unknown	Yong Chen	210	2020-09-01	2021-01-07
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma Pegylated liposomal doxorubicin, Anlotinib - Stage III Adult Soft Tissue Sarcoma	Phase 2	Unknown	Yong Chen	45	2020-04-01	2021-02-21

Conditions studied

Melanoma (2)  ·  Sarcoma (1)

Interventions

Temozolomide (2)  ·  Endostatins (1)  ·  SHR-1701 (1)  ·  anlotinib (1)  ·  endostar protein (1)  ·  liposomal doxorubicin (1)

Countries

China (4)